Literature DB >> 7912732

Oral candidiasis and immune status of HIV-infected patients.

H Nielsen1, K D Bentsen, L Højtved, E H Willemoes, F Scheutz, M Schiødt, K Stoltze, J J Pindborg.   

Abstract

A total of 84 HIV-infected homosexual men having either normal oral mucosa (NOM), erythematous candidiasis (EC) or pseudomembranous candidiasis (PsC) were included in the study. The patients were evaluated by median number of peripheral CD4+ cells, CD8+ cells and by lymphocyte function assessed by poke-weed mitogen test. There was a significant difference between CD4+ counts among patients with the two subtypes of candidiasis (95% CI of median difference: 10-240/mm3; P = 0.03), but not for pokeweed mitogen response. Survival analysis showed that after 2 y there was no significant difference in development of AIDS between patients with EC and PsC (P = 0.29). If patients with both types of oral candidiasis were pooled and compared with patients with NOM, a significant difference in development of AIDS was found (P = 0.04). It is concluded that HIV-infected patients with oral candidiasis of any subtype (EC or PsC) are significantly more immune suppressed and show a faster development of AIDS than HIV-infected patients with NOM. However, in this cohort, EC and PsC are of equal importance as predictors for immune suppression and AIDS development.

Entities:  

Mesh:

Year:  1994        PMID: 7912732     DOI: 10.1111/j.1600-0714.1994.tb01102.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  15 in total

Review 1.  The significance of oral health in HIV disease.

Authors:  I L Chapple; J Hamburger
Journal:  Sex Transm Infect       Date:  2000-08       Impact factor: 3.519

2.  Macrophage-mediated responses to Candida albicans in mice expressing the human immunodeficiency virus type 1 transgene.

Authors:  Mathieu Goupil; Emilie Bélanger Trudelle; Véronique Dugas; Catherine Racicot-Bergeron; Francine Aumont; Serge Sénéchal; Zaher Hanna; Paul Jolicoeur; Louis de Repentigny
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

3.  Carriage frequency, intensity of carriage, and strains of oral yeast species vary in the progression to oral candidiasis in human immunodeficiency virus-positive individuals.

Authors:  Kaaren G Vargas; Sophie Joly
Journal:  J Clin Microbiol       Date:  2002-02       Impact factor: 5.948

Review 4.  Oral manifestations in HIV infection: fungal and bacterial infections, Kaposi's sarcoma.

Authors:  Peter A Reichart
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

5.  Ca3 fingerprinting of Candida albicans isolates from human immunodeficiency virus-positive and healthy individuals reveals a new clade in South Africa.

Authors:  Elaine Blignaut; Claude Pujol; Shawn Lockhart; Sophie Joly; David R Soll
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

Review 6.  Candida-host interactions in HIV disease: implications for oropharyngeal candidiasis.

Authors:  P L Fidel
Journal:  Adv Dent Res       Date:  2011-04

Review 7.  Importance of Candida-bacterial polymicrobial biofilms in disease.

Authors:  Melphine M Harriott; Mairi C Noverr
Journal:  Trends Microbiol       Date:  2011-08-19       Impact factor: 17.079

8.  Importance of beta2-microglobulin in murine resistance to mucosal and systemic candidiasis.

Authors:  E Balish; F A Vazquez-Torres; J Jones-Carson; R D Wagner; T Warner
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

Review 9.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Oral manifestations as predictors of immune suppression in a HIV-/AIDS-infected population in south India.

Authors:  Gaurav Sharma; Keerthilatha M Pai; Suhas Setty; John T Ramapuram; Archna Nagpal
Journal:  Clin Oral Investig       Date:  2008-07-31       Impact factor: 3.573

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.